Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS

被引：1
|
作者：
Peck-Radosavljevic, M. [1 ,2 ]
Kudo, M. [3 ]
Lee, H. C. [4 ]
Cheng, A. -Lii [5 ]
Nakajima, K. [6 ]
Raoul, J. -L. [7 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Klinikum Klagenfurt Worthersee, Klagenfurt, Austria
[3] Kindai Univ, Fac Med, Osaka, Japan
[4] Asan Med Ctr, Seoul, South Korea
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Inst Cancerol Ouest, Digest Oncol, Nantes, France
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30614-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-164
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [21] Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial
    Han, Guohong
    Yang, Jijin
    Shao, Guoliang
    Teng, Gaojun
    Wang, Maoqiang
    Yang, Jianyong
    Liu, Zhaoyu
    Feng, Gansheng
    Yang, Renjie
    Lu, Ligong
    Chao, Yee
    Wang, Jianhua
    FUTURE ONCOLOGY, 2013, 9 (03) : 403 - 410
  • [22] AN INTERNATIONAL OBSERVATIONAL STUDY TO ASSESS THE USE OF SORAFENIB AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS
    Peck-Radosavljevic, M.
    Raoul, J. -L.
    Lee, H. C.
    Kudo, M.
    Nakajima, K.
    Cheng, A. -L.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S858 - S858
  • [23] OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
    Peck-Radosavijevic, Markus
    Raoul, Jean-Luc
    Lee, Han Chu
    Kudo, Masatoshi
    Nakajima, Keiko
    Chong, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
  • [25] Changes in liver function following real-world transarterial chemoembolization (TACE) in US patients (pts) with hepatocellular carcinoma (HCC): The LiverT study
    Miksad, Rebecca A.
    Ogasawara, Sadahisa
    Xia, Fang
    Fellous, Marc Mardoche
    Piscaglia, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Ciani, Oriana
    Sommariva, Silvia
    Tarricone, Rosanna
    VALUE IN HEALTH, 2017, 20 (03) : 336 - 344
  • [27] CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib
    Zhang, Lin
    Yang, Hongcai
    Ning, Shangkun
    Wu, Zhijuan
    Wang, Dianzhe
    Liang, Hexin
    Wang, Chunni
    Chang, Xu
    CANCER MEDICINE, 2024, 13 (12):
  • [28] Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization
    Wu, S. E.
    Charles, H. W.
    Park, J. S.
    Goldenberg, A. S.
    Deipolyi, A. R.
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2017, 98 (01) : 37 - 42
  • [29] Cerebral Lipiodol Embolism in Hepatocellular Carcinoma Patients Treated with Transarterial Embolization/Chemoembolization
    Chu, Hai-Jui
    Lee, Chung-Wei
    Yeh, Shin-Joe
    Tsai, Li-Kai
    Tang, Sung-Chun
    Jeng, Jiann-Shing
    PLOS ONE, 2015, 10 (06):
  • [30] A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
    Lee, Hae Lim
    Kim, Seok Hwan
    Kim, Hee Yeon
    Lee, Sung Won
    Song, Myeong Jun
    FRONTIERS IN ONCOLOGY, 2024, 14
12345